Hydroxyurea and sickle cell crisis

Peter T.c. ho, Anthony J. Murgo, Richard T. Silver, Samuel Charache, George J. Dover, Richard D. Moore, Michael L. Terrin

Research output: Contribution to journalLetter

Abstract

To the Editor: Charache et al. (May 18 issue)1 reported on the efficacy of hydroxyurea in ameliorating some of the complications of sickle cell anemia. In a randomized, double-blind setting, hydroxyurea treatment was associated with a reduced frequency of vaso-occlusive crises, acute chest syndrome, and transfusions, but not of stroke, hepatic sequestration, or death. As the authors emphasized, the encouraging results of this study must be balanced by concern over the carcinogenic or leukemogenic potential of long-term hydroxyurea therapy. In an accompanying editorial, Schechter and Rodgers2 state, “There has been extensive experience with [hydroxyurea's] long-term use – at slightly higher.

Original languageEnglish (US)
Pages (from-to)1008-1009
Number of pages2
JournalNew England Journal of Medicine
Volume333
Issue number15
DOIs
StatePublished - Oct 12 1995

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Hydroxyurea and sickle cell crisis'. Together they form a unique fingerprint.

  • Cite this

    ho, P. T. C., Murgo, A. J., Silver, R. T., Charache, S., Dover, G. J., Moore, R. D., & Terrin, M. L. (1995). Hydroxyurea and sickle cell crisis. New England Journal of Medicine, 333(15), 1008-1009. https://doi.org/10.1056/NEJM199510123331514